Clinical trials: IPMN, open to volunteers
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
IPMN, Pancreatic, Pancreatic Cancer, Resected
Venous Resection in Patients Undergoing Pancreatic Surgery
Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved.
- Conditions
- IPMN, Pancreatic, Pancreatic Cancer, Resected, Pancreatic Cancer Borderline, Chronic Pancreatitis
- Trial name
- VENUS (NCT07621029)
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 1,000 people
- Sponsor
- Sahlgrenska University Hospital
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, Diagnose Disease
AI-Powered Precision Decision-Making for Pancreatic Diseases
This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases.
- Conditions
- Pancreatic Cancer, Diagnose Disease, IPMN, Pancreatic, Pancreatic Cystic Lesions
- Trial name
- NCT07439757
- Testing
- Diagnosis by Artificial Intelligence model
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Changhai Hospital
Pancreas Head Cancer, Pancreas Adenocarcinoma
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of…
- Conditions
- Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic, Cholangio Carcinoma
- Trial name
- PANENCA (NCT07262957)
- Testing
- HOP bundle
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
IPMN, Pancreatic
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Intraductal papillary mucinous neoplasms (IPMN) are one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC), a lethal disease predicted to become the second leading cause of cancer-related deaths in Western…
- Trial name
- NCT06574373
- Testing
- Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention
- Where
- 2 sites in Italy
- Volunteers
- 3,600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Pancreatic Cancer, IPMN, Pancreatic
Pancreatic Cancer Initial Detection Via Liquid Biopsy
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient…
- Conditions
- Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk, Chronic Pancreatitis
- Trial name
- PANCAID (NCT06283576)
- Testing
- Liquid biopsy
- Where
- Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
IPMN, Pancreatic, IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure.
- Trial name
- MAPS (NCT05117723)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's Hospital Melbourne